Related Articles
The effectiveness of plasma miR‑33a‑5p as a predictive biomarker for the efficacy of colorectal cancer chemotherapy
Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials
Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first‑line treatment of metastatic colorectal cancer
Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs
Association between the expression of microRNAs and the response of patients with locally advanced rectal cancer to preoperative chemoradiotherapy